DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Alport Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Alport Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Alport Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Alport Syndrome: An Overview
According to the National Organization for Rare Disorders (NORD), Alport Syndrome is a rare genetic disorder characterized by progressive kidney disease and abnormalities of the inner ear and the eye. It is also known as hereditary nephritis and has three genetic types: autosomal recessive (ARAS), X-linked(XLAS), and autosomal dominant (ADAS). X-linked Alport Syndrome (XLAS) is the most common, and affected males typically have more severe disease than affected females.
Individuals with Alport Syndrome experience symptoms such as hematuria, proteinuria, high blood pressure, and gradual loss of kidney function. Some individuals also develop hearing loss and vision problems, including cataracts and retinopathy. The hallmark of the disease is hematuria early in life, with progressive decline in kidney function (kidney insufficiency) that ultimately results in end-stage renal disease and kidney failure, especially in affected males.
Alport Syndrome Market Key Facts
-
According to the National Organization for Rare Disorders (NORD) (2019), Alport Syndrome is estimated to affect approximately 1 in 5,000-10,000 people in the general population in the United States, which means that approximately 30,000-60,000 people in the United States have the disorder.
-
As per Watson et al. (2023), Alport Syndrome affects about 1 in 50,000 newborns, and males are more likely to be symptomatic than females. It is estimated that approximately 30,000 to 60,000 people in the US have this disorder. It affects roughly 2.2% of children and 0.2% of adults with ESRD in the US, while in Europe, it accounts for 0.6% of patients with ESRD.
-
According to the National Organization for Rare Disorders (NORD) (2020), approximately 50% of untreated males with XLAS have renal failure by the age of 25, increasing to 90% by the age of 40, and nearly 100% by the age of 60. While females with XLAS do not develop renal insufficiency until much older.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Alport Syndrome pipeline therapies. It also thoroughly assesses the Alport Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Alport Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Alport Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Alport Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Alport Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Alport Syndrome Epidemiology, Segmented as -
-
Total Prevalent Cases of Alport Syndrome in the 7MM [2019–2032]
-
Treated Cases of Alport Syndrome in the 7MM [2019–2032]
-
Total Diagnosed Prevalent Cases of Alport Syndrome in the 7MM [2019–2032]
-
Age-specific Cases of Alport Syndrome in the 7MM [2019–2032]
-
Type-specific Cases of Alport Syndrome in the 7MM [2019–2032]
-
Gender-specific Cases of Alport Syndrome in the 7MM [2019–2032]
Alport Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Alport Syndrome market or expected to be launched during the study period. The analysis covers the Alport Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Alport Syndrome drugs based on their sale and market share.
The report also covers the Alport Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Alport Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Alport Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/alport-syndrome-market
Alport Syndrome Therapeutics Analysis
While there is no cure for Alport Syndrome, management focuses on controlling symptoms and slowing down the progression of proteinuria and kidney disease. Treatment options may include medications to manage blood pressure and proteinuria, dietary modifications, hearing aids or cochlear implants for hearing loss and regular monitoring of kidney function. Use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), and diuretics are preferred. In some cases, kidney transplantation may be necessary for individuals with end-stage kidney disease (ESKD). However, even with a transplant, there is a risk of the disease affecting the new kidney. Therefore, long-term monitoring and management are essential.
There is a need for therapies that are curative and not just slow but arrest disease progression. Several major pharma and biotech companies are developing therapies for Alport Syndrome. Currently, Reata Pharmaceuticals is leading the therapeutics market with its Alport Syndrome drug candidates in the most advanced stage of clinical development. A few emerging therapies such as Eloxx Pharmaceutical’s ELX-02, River 3 Renal Corp’s R3R0, and others are expected to launch during the forecast period and have the potential to impact the treatment and market paradigm.
Alport Syndrome Companies Actively Working in the Therapeutics Market Include
-
Eloxx Pharmaceuticals, Inc.
-
Chinook Therapeutic
-
River 3 Renal Corp.
-
Travere Therapeutics, Inc.
-
Reata Pharmaceuticals, Inc.
And Many Others
Emerging and Marketed Alport Syndrome Therapies Covered in the Report Include:
-
Bardoxolone: Reata Pharmaceuticals, Inc.
-
R3R01: River 3 Renal Corp
-
FILSPARI (sparsentan): Travere Therapeutics
-
ELX-02: Eloxx Pharmaceuticals
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/alport-syndrome-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Alport Syndrome Competitive Intelligence Analysis
4. Alport Syndrome Market Overview at a Glance
5. Alport Syndrome Disease Background and Overview
6. Alport Syndrome Patient Journey
7. Alport Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Alport Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Alport Syndrome Unmet Needs
10. Key Endpoints of Alport Syndrome Treatment
11. Alport Syndrome Marketed Therapies
12. Alport Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Alport Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Alport Syndrome Market Outlook (In US, EU5, and Japan)
16. Alport Syndrome Companies Active in the Market
17. Alport Syndrome Access and Reimbursement Overview
18. KOL Views on the Alport Syndrome Market
19. Alport Syndrome Market Drivers
20. Alport Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/alport-syndrome-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Postoperative Nausea and Vomiting (PONV) Market
"Postoperative Nausea and Vomiting (PONV) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Postoperative Nausea and Vomiting market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Postoperative Nausea and Vomiting market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research
